Summarized by Masters of Longevity from Longevity Technology.
Longeveron’s upcoming conference appearances promise updates and networking on aging research, investment trends, and its stem-cell development programs.
Key Takeaways
- Longeveron will attend three longevity and aging investment conferences in October across Boston, a virtual event, and South San Francisco.
- The company highlighted laromestrocel (Lomecel-B) as an investigational mesenchymal stem cell therapy with potential anti-inflammatory and regenerative effects.
- Longeveron reported a medRxiv preprint from a Phase 2a post hoc analysis and cited Phase 2b Cell Stem Cell results and a $1,000,000 XPRIZE Healthspan award.
